This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here. Traders work on the floor of the New York Stock Exchange during morning trading on Oct. 4, … Read more
This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here. Traders work on the floor during morning trading at the New York Stock Exchange (NYSE) on March … Read more
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Rally in markets: Stocks were higher across the board Tuesday afternoon, led by the Nasdaq Composite , which added 0.7% and was on pace for back-to-back … Read more
A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Scott Olson | Getty Images The Food and Drug Administration on Tuesday approved Eli Lilly‘s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S. The … Read more
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Eli Lilly, Novo Nordisk and other drugmakers showed off encouraging data … Read more
As some of the market’s hottest stocks take a pause, CNBC’s Jim Cramer on Tuesday told investors it may be wise to get into some “slowdown stocks,” like companies with products related to pets. Cramer suggested the “post-Covid drought” in these stocks could be over and pinpointed three: online retailer Chewy, animal health care company … Read more
Novo Nordisk’s Wegovy weight loss drug has seen a meteoric rise in popularity. Nurphoto | Getty Images Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world’s second largest economy. China’s National Medical Products Administration “recently” … Read more
Constellation Brands has an upper hand in a battle for coveted — but shrinking — territory in stores, according to new Wall Street research. It is further evidence that the Mexican beer powerhouse is a worthwhile investment in an otherwise weak category. Constellation’s portfolio of beers, anchored by Modelo and Corona, is among the best … Read more
Novo Nordisk’s new manufacturing facility in Clayton, North Carolina. Courtesy: Novo Nordisk Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. Demand for … Read more
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year. If cleared by the Food and Drug Administration, the company plans to launch Zepbound for so-called obstructive … Read more
